Compounded Semaglutide & Tirzepatide in 2026: What Is Actually Still Legal
The short version: compounding didn't become illegal, but the broad "shortage exemption" that let pharmacies mass-produce semaglutide and tirzepatide for essentially any patient is gone. What remains is a narrow individual-patient exception. Here is the actual regulatory timeline, what qualifies under the current standard, and how to tell whether a telehealth platform offering compounded GLP-1s in May 2026 is operating within it.
The regulatory timeline
Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) both could not meet commercial demand for their branded GLP-1s. Under FDA rules, a listed drug shortage lets 503A and 503B pharmacies compound the drug more broadly than they otherwise could - this is the exemption that fueled the 2023-2024 compounded-GLP1 telehealth boom.
With Eli Lilly's tirzepatide supply resolved, the FDA ended the shortage-based enforcement discretion that let 503A pharmacies compound tirzepatide broadly. 503A pharmacies could no longer rely on the shortage exemption after this date.
The larger-scale 503B outsourcing facilities lost their shortage-based exemption for tirzepatide roughly a month later, closing the largest-volume compounding channel for that molecule.
Novo Nordisk's semaglutide shortage was declared resolved on a similar but separately-tracked timeline, closing the shortage-based exemption for semaglutide compounding as well.
The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely. If finalized, this would close large-scale 503B compounding of these molecules on an ongoing basis, leaving only the narrow 503A individual-patient exception as a legal compounding path.
Sources: FDA shortage database, FDA 503B Bulks List proposed rule (accessdata.fda.gov), pharmacytimes.com regulatory coverage. See full sources.
What a 503A pharmacy can still legally compound
The individual-patient exception survives the shortage exemption closing. A licensed 503A pharmacy can compound semaglutide or tirzepatide for a specific patient when there is a documented clinical justification:
- A prescriber-specified dose not commercially available in the FDA-approved product
- A documented allergy to an excipient or component of the branded formulation
- A specific clinical need the prescriber documents in writing
Cost savings alone does NOT qualify as a valid basis under current FDA guidance.
How to verify a pharmacy before ordering
- Ask what clinical justification basis they use. A legitimate operation should explain why your specific case qualifies under the individual-patient exception, not just process payment and ship.
- Verify PCAB accreditation independently- search the Pharmacy Compounding Accreditation Board's directory rather than trusting a platform's own claim.
- Confirm the pharmacy's state licensethrough your state board of pharmacy's license lookup tool.
- Be skeptical of "unrestricted for any patient" offers. If a platform in May 2026advertises compounded semaglutide or tirzepatide as routinely available to any patient regardless of clinical need, that framing doesn't match the current regulatory standard.
- Never use "research peptide" or international sellers. These operate entirely outside the licensed-pharmacy framework - no prescriber oversight, no accreditation, unverified purity and dosing accuracy. Not legal for human use.
If compounded isn't an option, what is the cheapest legal path?
The market genuinely shifted since 2023-2024. Manufacturer self-pay programs on the weight-loss-indicated brands are now the realistic cash-pay floor:
Frequently asked questions
Is compounded semaglutide illegal now?
No - but the legal basis narrowed dramatically. Compounding is always legal when a licensed 503A or 503B pharmacy is filling an individual prescription for a documented clinical need. What ended was the FDA drug-shortage exemption that let compounders mass-produce semaglutide for essentially any patient regardless of individual need, simply because Novo Nordisk could not meet commercial demand. Once the FDA declared the shortage resolved, that broad exemption disappeared - compounding didn't become illegal, but the "cheap semaglutide for anyone at any dose" business model that dominated 2023-2024 telehealth lost its regulatory footing.
What specifically changed, and when?
The FDA ended enforcement discretion for 503B outsourcing facilities compounding tirzepatide on March 19, 2025, and for 503A pharmacies on February 18, 2025 - both tied to Eli Lilly resolving the tirzepatide supply shortage. Semaglutide followed a similar but separately-timed path as Novo Nordisk resolved its own shortage. Then on April 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely - a move that, if finalized, would close large-scale compounded GLP-1 production by outsourcing facilities for good, leaving only narrow 503A individual-patient compounding as a legal path.
What can a 503A pharmacy still legally compound in 2026?
A narrow, individual-patient exception: a licensed 503A pharmacy can compound semaglutide or tirzepatide for a specific patient when there is a documented clinical justification - a prescriber-specified non-standard dose not commercially available, a documented allergy to a component of the FDA-approved product, or a similar individualized medical need. Cost savings alone does NOT qualify as a valid basis under FDA guidance. This is a meaningfully different standard than "any patient who wants a cheaper option," which is what most 2023-2024 telehealth compounding operated under.
How do I know if a telehealth platform offering compounded GLP-1s is operating legally in 2026?
Ask directly what clinical justification basis they are using - a legitimate 503A pharmacy filling under the individual-patient exception should be able to explain why your specific case qualifies (non-standard dose, documented allergy, etc.), not just process a payment. Verify the pharmacy's state license and PCAB (Pharmacy Compounding Accreditation Board) accreditation independently rather than trusting a platform's own claims. If a platform advertises compounded semaglutide or tirzepatide as a routine, unrestricted option for any patient in 2026, that is a signal the operation may not be complying with the post-shortage regulatory standard - proceed with caution and verify independently before ordering.
What about "research peptide" sellers - are those legal?
No. Products marketed as "research chemicals," "research peptides," or similar, sold without a prescription and without pharmacy licensing, are not legal for human use regardless of what they contain. These operate entirely outside the pharmacy-compounding regulatory framework described above - no prescriber oversight, no pharmacy accreditation, no quality control standards, and no legal sales channel for human consumption. Purity, dosing accuracy, and contamination risk are unverified and unregulated. Avoid these sources entirely; they are a different (and much riskier) category than a licensed 503A pharmacy operating under the individual-patient exception.
If compounded is mostly closed off now, what is the actual cheapest legal path?
For most cash-pay patients in 2026, the manufacturer self-pay programs on the weight-loss-indicated brands are now the realistic cost floor: NovoCare for Wegovy, LillyDirect for Zepbound, and LillyDirect for Foundayo (orforglipron). These didn't exist at the scale or price point they do now back when compounding dominated the cash-pay conversation in 2023-2024 - the market has genuinely shifted. See the without-insurance guides linked below for current pricing by drug.
Does this affect patients who already have a compounded prescription filled before the rule change?
The regulatory change affects what pharmacies can newly compound going forward, not retroactively invalidate prescriptions already filled. If you have an existing compounded GLP-1 relationship with a 503A pharmacy, ask them directly whether they can continue filling your prescription under the individual-patient exception - many patients with documented clinical needs (dose customization, allergies) can continue, while patients whose only basis was general cost savings likely cannot get new fills under the current standard.
Related guides
Stay ahead of every GLP-1 development
We'll email you when something actually matters: new FDA approvals (Foundayo, CagriSema, retatrutide), pricing drops at LillyDirect/NovoCare, telehealth deals, clinical trial results, FDA recalls, and insurance policy changes. ~1-2 emails/month. No filler.